Onkolojik Tedaviye Bağlı Miyokard Fonksiyonlarında Bozulma ve Kalp Yetersizliği

Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., et al.. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). European Heart Journal, 37(36), 2768–2801. https://doi.org/10.1093/eurheartj/ehw211

Armenian, S. H., Lacchetti, C., Barac, A., et al.Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 35(8), 893–911. https://doi.org/10.1200/JCO.2016.70.5400

Curigliano G.,Lenihan D.,Ganatra S., et al Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations | Elsevier Enhanced Reader. (n.d.). https://doi.org/10.1016/j.annonc.2019.10.023

Pouna, P., Bonoron-Adèle, S., Gouverneur, G.,et al. (1996). Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention. British Journal of Pharmacology, 117(7), 1593–1599.

Mortanse S. A.,Olsen S.,Baandup U., et al.Chronic anthracycline cardiotoxicity: Haemodynamic and histopathological manifestations suggesting a restrictive endomyocardial disease. (n.d.). Retrieved January 9, 2021, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1232165/

Doroshow, J. H. (1983). Anthracycline Antibiotic-stimulated Superoxide, Hydrogen Peroxide, and Hydroxyl Radical Production by NADH Dehydrogenase. 43, 10.

Fang X, Wang H, Han D, Xie E, Yang X, Wei J, et al. Ferroptosis as a target for protection againstcardiomyopathy.ProcNatlAcadSciUSA.2019;116(7):2672–80.https://doi.org/10.1073/pnas. 1821022116.

Kleiner, Y., Bar-Am, O., Amit, T., et al. (2008). TVP1022 and Propargylamine Protect Neonatal Rat Ventricular Myocytes Against Doxorubicin-Induced and Serum Starvation-Induced Cardiotoxicity.JournalofCardiovascularPharmacology,52(3),268–277.https://doi.org/10.1097/FJC.0b013e3181862441

Jirkovský E, Popelová O, Křiváková-Staňková P, et al. Chronic anthracycline cardiotoxicity: molecular and functional analysis with focus on nuclear factor erythroid 2- related factor 2 and mitochondrial biogenesis pathways. J Pharmacol Exp Ther. 2012;343(2):468–78. https://doi.org/10.1124/jpet.112.198358.

Nebigil CG, Désaubry L. Updates in anthracyclinemediated cardiotoxicity. Front Pharmacol. 2018;9(NOV). https://doi.org/10.3389/fphar.2018. 01262

Rajagopalan, S., Politi, P. M., Sinha,et al.(1988). Adriamycin-induced Free Radical Formation in the Perfused Rat Heart: Implications for Cardiotoxicity. Cancer Research, 48(17), 4766–4769.

Helmes M.,Trombia K.,Granzier H., at al.(2021)Titin Develops Restoring Force in Rat Cardiac Myocytes | Circulation Research. (n.d.). Retrieved January 9, 2021, from

M.S. Ewer, M.K. Ali, B. Mackay, et al.A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving adriamycinJ Clin Oncol, 2 (1984), pp. 112-117

Gregory M.,Cote M.D.,Dousglas B.,et al.ERBB2 Inhibition and Heart Failure | NEJM. (n.d.). Retrieved January 9, 2021, from https://www.nejm.org/doi/10.1056/NEJMcibr1203156

Cardinale Daniela, Sandri Maria T., Colombo Alessandro, et al. (2004). Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy.Circulation,109(22),2749–2754. https://doi.org/10.1161/01.CIR.0000130926.51766.CC

Kupari M, Volin L, Suokas A, et al. Cardiac involvement in bone marrow transplantation: electrocardiographic changes, arrhythmias, heart failure and autopsy findings. Bone Marrow Transplant. 1990;5: 91–98.

Gottdiener JS, Appelbaum FR, Ferrans VJ, et al. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med. 1981;141:758–763

Quezado ZM, Wilson WH, Cunnion RE, et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med. 1993;118:31–36.

Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352(22):2302–13.

Biganzoli L, Cufer T, Bruning P, et al. Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European Organization for Research and Treatment of Cancer multicenter trial. Cancer. 2003;97(1):40

Rowinsky EK, McGuire WP, Guarnieri T, et al. Cardiac disturbances during the administration of Taxol. J Clin Oncol. 1991;9:1704–1712.(artimi yaptığını gösteren yazı )